Updates on Managing Metastatic Uveal Melanoma: What Pharmacists Need to Know

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Immunocore LLC.

Registration & Dates for Activities

Tues., April 16, 2024
3:00-4:00 PM ET

Thurs., April 25, 2024
1:00-2:00 PM ET


Jordan P. McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist, Melanoma and Non-Melanoma Skin Cancer
Huntsman Cancer Institute
Adjunct Assistant Professor
University of Utah College of Pharmacy
Salt Lake City, Utah


The clinical reviewer, Megan May, PharmD, BCOP has no relevant affiliations or financial relationships with a commercial interest to disclose.

Susanne Batesko-Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

All relevant financial relationships have been mitigated.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0430-0000-24-033-L01-P
Credits: 1.0 hour (0.01 ceu)
Estimated time to complete activity: 60 minutes

Type of Activity: Application
Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 60-minutes.


This activity has been designed to meet the needs of Oncology, managed care and specialty pharmacists.


Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the post-test and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this educational activity is to provide oncology, managed care, and specialty pharmacists with advanced and up-to-date knowledge of recent advances in the treatment of metastatic uveal melanoma (mUM), including novel therapies, approved indications, and treatment-related adverse events, which will serve to positively impact patient care and outcomes.


Upon completion of this program, participants should be better able to:

  • Describe uveal melanoma including the pathophysiology of metastatic disease
  • Discuss currently approved agents for the treatment of metastatic uveal melanoma
  • Explain the profiles of emerging novel agents, including mechanisms of action, efficacy, and safety data
  • Recognize common treatment-related adverse events with such therapies and approaches for mitigation


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Immunocore LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.

There are no available webinars at this time.